Open Access

Tableau II.

Principaux essais cliniques utilisant un mélange d’anticorps en oncologie. *Développement stoppé.

Indication thérapeutique Anticorps Formulation Cibles Phase clinique Date
Cancer colorectal/cancer du poumon MM-151 Unique 3xEGFR Phase I* 2015

Cancer colorectal/cancer du poumon MM-151 + MM-121 Séparée 3xEGFR + HER3 Phase I* 2015

Cancer colorectal/glioblastome Sym004: futuximab + modotuximab Unique 2xEGFR Phase II 2018

Cancers épithéliaux Sym013 Plusieurs cellules 2xEGFR + 2xHER2 + 2x HER3 Phase II* 2016

Tumeurs cMET-amplifié Sym015 Plusieurs cellules 2xcMET Phase II 2016

Cancer du sein Bispécifique MCLA-128 Cellule unique HER2/HER3 Phase I 2017

Leucémie myéloïde aiguë Bispécifique MCLA-117 Cellule unique CLEC12A/CD3 Phase I 2017

Cancer colorectal Bispécifique MCLA-158 Cellule unique LGR5/EGFR Phase I 2018

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.